Panel: Approve, but limit Amgen PCSK9; payers have final say
This article was originally published in Scrip
Executive Summary
Forget blockbuster status, makers of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors.
You may also be interested in...
Phase III Boost For Esperion But Does It Own Its Destiny?
Esperion will be allowed to enroll patients on high dose statins into the Phase III pivotal trial of its cholesterol lowering drug bempedoic acid, but with competing products ahead in the race, the product faces an uphill battle for market share even if it does garner approval.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.